Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Recurrent or progressive Non-Small Cell Lung Cancer stage IV or IIIB patients with Histologic or cytologic confirmation.
Wild type epidermal growth factor receptor status.
Progressed after first-line chemotherapy.
No previous systemic anticancer therapy.
Measurable lesion according to response evaluation criteria in solid tumors with at least one measurable lesion not previously irradiated.
Provision of written informed consent.

Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).
Positive epidermal growth factor receptor mutation.
Known severe hypersensitivity to icotinib or any of the excipients of this product.
Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.

Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR